Bisphosphonate-Associated Osteonecrosis of the Jaw Bone Neoplasms
Conditions
Interventions
This is an observational historical cohort study design with a cross-sectional approach. The objective of the study is to evaluate the incidence, risk factors, and clinical-tomographic staging of Medi
s first zoledronic acid infusion (within the study&apos
s reference period) until the date of the current clinical dental evaluation or the date of death recorded in the medical system
Sponsors
Universidade Estadual do Centro Oeste
Universidade Estadual do Centro Oeste
Eligibility
Inclusion criteria
Inclusion criteria: Pacientes oncológicos; de ambos os sexos; que iniciaram o ciclo terapêutico com ácido zoledrônico (Zometa®) no período compreendido entre janeiro de 2023 e dezembro de 2024, independentemente da continuidade da terapia em anos subsequentes
Exclusion criteria
Exclusion criteria: Patients who progressed to death; or who present severe systemic debility (as documented in the medical records) that prevents in-person participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to early identify the incidence of Medication-Related Osteonecrosis of the Jaw (MRONJ) Stage 0 cases, verified by means of systematic cross-referencing between intraoral clinical examination and Computed Tomography imaging analysis guided by a structured template, based on the observation of the frequency (in percentage) of prodromal radiographic findings such as focal bone sclerosis, thickening of the lamina dura, and persistent alveolar socket post-extraction in patients who do not present frank mucosal bone exposure | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to demonstrate the direct correlation between the absence of prophylactic oral adequacy and the exacerbation of maxillofacial bone toxicity, verified by means of medical records analysis associated with the active search for local risk factors (such as tooth extractions performed during medication use and the presence of periodontal disease), based on the statistical finding that the highest percentages (%) of progression to severe clinical stages of American Association of Oral and Maxillofacial Surgeons (MRONJ) (AAOMS Stages 1, 2, and 3) occurred in the sample of patients subjected to traumatic risk factors while under zoledronic acid therapy | — |
Countries
BR
Contacts
Public ContactThalia da Silva
Universidade Estadual do Centro Oeste
Outcome results
None listed